Dr. Gajewski has developed experimental
vaccines against melanoma that are currently in Phase II clinical trials in a handful of patients at the University of Chicago Hospitals.
Not exact matches
As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective
against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in
vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.
We assess spontaneous and
vaccine - induced immune responses
against melanoma, and have a particular interest in developing methods for understanding functional subpopulations within
melanoma and the optimal ways of targeting them therapeutically.
At first, analyzing a patient's surgically removed tumor and developing a
vaccine against 10 specific targets on the tumor took nine months, says Greg Lizée, Ph.D., associate professor of
Melanoma Medical Oncology, whose research focuses on the immune system.
Dr. Gajewski has been awarded the grant to pursue his investigation of
vaccines against a type of skin cancer called
melanoma.